{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:38:24Z","timestamp":1777451904824,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eczema vaccinatum is the most common severe pathology associated with smallpox vaccination (vaccinia virus), occurring at high rates among individuals with a previous history of atopic dermatitis (atopic eczema).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Monoclonal antibodies capable of neutralizing vaccinia virus, anti-H3 and anti-B5, were developed as a potential therapy for treatment of human eczema vaccinatum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Using a small animal model of eczema vaccinatum, we demonstrated that both murine and fully human monoclonal antibodies effectively limited eczema vaccinatum disease, foreshortening both the disease kinetics and the severity of the erosive viral skin lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These neutralizing antibodies would likely be effective at reducing or eliminating clinical disease in people with eczema vaccinatum or other severe side effects of the smallpox vaccine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp1717","type":"journal-article","created":{"date-parts":[[2011,1,11]],"date-time":"2011-01-11T14:56:02Z","timestamp":1294757762000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Protective Murine and Human Monoclonal Antibodies against Eczema Vaccinatum"],"prefix":"10.1177","volume":"16","author":[{"given":"Yoshiaki","family":"Tomimori","sequence":"first","affiliation":[{"name":"Division of Cell Biology, La Jolla Institute for Allergy and Immunology (LIAI), La Jolla, CA, USA"},{"name":"Present address: Asubio Pharma, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Division of Cell Biology, La Jolla Institute for Allergy and Immunology (LIAI), La Jolla, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan M","family":"McCausland","sequence":"additional","affiliation":[{"name":"Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology (LIAI), La Jolla, CA, USA"},{"name":"Present address: Emory University School of Medicine, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Ando","sequence":"additional","affiliation":[{"name":"Division of Cell Biology, La Jolla Institute for Allergy and Immunology (LIAI), La Jolla, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilia","family":"Koriazova","sequence":"additional","affiliation":[{"name":"Kyowa Hakko Kirin California, La Jolla, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Kato","sequence":"additional","affiliation":[{"name":"Kyowa Hakko Kirin California, La Jolla, CA, USA"},{"name":"Present address: Kyowa Hakko Kirin, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Division of Cell Biology, La Jolla Institute for Allergy and Immunology (LIAI), La Jolla, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane","family":"Crotty","sequence":"additional","affiliation":[{"name":"Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology (LIAI), La Jolla, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2011,1,1]]},"reference":[{"key":"bibr1-IMP1717","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2006.00392.x"},{"key":"bibr2-IMP1717","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.4.555"},{"key":"bibr3-IMP1717","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0912134107"},{"key":"bibr4-IMP1717","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00021-09"},{"key":"bibr5-IMP1717","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.08.003"},{"key":"bibr6-IMP1717","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1573"},{"key":"bibr7-IMP1717","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01593-09"},{"key":"bibr8-IMP1717","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00906-07"},{"key":"bibr9-IMP1717","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0510598103"},{"key":"bibr10-IMP1717","volume-title":"Smallpox and its eradication.","author":"Fenner F.","year":"1988"},{"key":"bibr11-IMP1717","doi-asserted-by":"publisher","DOI":"10.1086\/375824"},{"key":"bibr12-IMP1717","doi-asserted-by":"publisher","DOI":"10.1086\/375825"},{"key":"bibr13-IMP1717","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2005.12.001"},{"key":"bibr14-IMP1717","doi-asserted-by":"publisher","DOI":"10.1086\/422999"},{"key":"bibr15-IMP1717","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.200600926"},{"key":"bibr16-IMP1717","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.18.11724-11733.2005"},{"key":"bibr17-IMP1717","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02244-07"},{"key":"bibr18-IMP1717","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01797-08"},{"key":"bibr19-IMP1717","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/9.3.461"},{"key":"bibr20-IMP1717","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.O-07-486"},{"key":"bibr21-IMP1717","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082835"},{"key":"bibr22-IMP1717","first-page":"2849","volume-title":"Fundamental Virology","author":"Moss B.","year":"2006","edition":"5"},{"key":"bibr23-IMP1717","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2004.07.024"},{"key":"bibr24-IMP1717","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-83-12-2915"},{"key":"bibr25-IMP1717","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601025103"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP1717","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP1717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:49:49Z","timestamp":1777380589000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP1717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.3851\/IMP1717"],"URL":"https:\/\/doi.org\/10.3851\/imp1717","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}